Search Results
Oct 19, 2025, 02:00 ET Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia
previous autologous hematopoietic stem cell transplantation and treatment with triple classes of drugs (proteasome inhibitor, immunomodulatory agent, and CD38 monoclonal antibody). By the screening period, his serum free light chain level had reached 10,374.86 mg/L. The patient underwent two CAR-T cell infusions
More news about: CARsgen Therapeutics
Oct 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
Company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor ("SCF") from binding to and signaling through the CD117 ("c-Kit") receptor on mast and stem cells. According to Jasper, the "SCF/c-Kit pathway is a survival signal for mast cells and [the Company] believe[s]
More news about: Pomerantz LLP
Oct 18, 2025, 01:00 ET SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
delighted that the excellent preclinical profile of our HPV-E7-specific TCR - including high avidity and dual functionality in both CD8+ and CD4+ T cells - has translated into clinical activity with SCG142" added Dr. Susanne Wilde, VP, Head of Preclinical Research of SCG
More news about: SCG Cell Therapy Pte Ltd
Oct 18, 2025, 01:00 ET SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
delighted that the excellent preclinical profile of our HPV-E7-specific TCR - including high avidity and dual functionality in both CD8+ and CD4+ T cells - has translated into clinical activity with SCG142" added Dr. Susanne Wilde, VP, Head of Preclinical Research of SCG
More news about: SCG Cell Therapy Pte Ltd
Oct 17, 2025, 10:00 ET Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
6.2Presentation number: 922MO About AMT-116AMT-116, a CD44v9 ADC, is composed of a proprietary antibody with high CD44v9 binding affinity, a hydrolysable linker, and a belotecan derivative payload (a novel and clinically validated topoisomerase-1
More news about: Multitude Therapeutics, Inc.
Oct 17, 2025, 10:00 ET 普眾發現在2025年歐洲腫瘤內科學會（ESMO）上公佈其抗CD44v9 ADC（AMT-116）用於晚期EGFR野生型非小細胞肺癌（NSCLC）及其他晚期實體瘤的初步積極數據
標題：Updated ongoing Phase I/II clinical trial results of AMT-116, a first-in-class anti-CD44v9 antibody-drug conjugate (ADC), in patients with advanced solid tumors 口頭匯報專題： Developmental therapeutics
More news about: 普眾發現
Oct 17, 2025, 09:50 ET Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
for early 2026. The Phase 1 study is testing GTB-3650 in patients battling relapsed or refractory blood cancers that express the CD33 protein, specifically acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These represent some of the most difficult cancer
More news about: Equity Insider
Oct 17, 2025, 09:08 ET CD Valet Shares October CD APY Checkpoint, Enabling Savers to Easily Market Test their CD Returns
lower than the median APY across all 12-month term CDs tracked on CD Valet. The average APY across any CD term from these banks is less than 2.00% (1.78% average APY). CD Valet is the most comprehensive source of CD rates available today, offering an online marketplace connecting
More news about: CD Valet
Oct 17, 2025, 09:00 ET Precision Oncology Approaches Drive $312B Market Transformation
for early 2026. The Phase 1 study is testing GTB-3650 in patients battling relapsed or refractory blood cancers that express the CD33 protein, specifically acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These represent some of the most difficult cancer
More news about: USA News Group
Oct 17, 2025, 08:00 ET OpenInfra Summit Europe Kicks Off in Paris: OpenInfra is the Resilience Playbook for AI, Sovereignty and VMware Migrations
contributors illustrating resilience in action: BMW and Workday shared how Zuul (OpenInfra's CI/CD gating system) helps prevent breakages before code lands, directly improving uptime and change velocity at scale.
More news about: OpenInfra Foundation
Oct 17, 2025, 01:32 ET FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States
indications, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), Crohn's disease (CD), ulcerative colitis (UC), and plaque psoriasis (Ps). HS and UV were previously approved in adult patients, and the latest approval expands these two
More news about: Celltrion USA
Oct 16, 2025, 17:31 ET Indolent Lymphoma Market Experiences Significant Growth Amid Evolving Therapeutic Landscape | DelveInsight
composed of four synthetic peptides. These microbial-derived, non-self peptides mimic CD8 HLA-A2 epitopes that resemble B cell–specific markers CD20, CD22, CD37, and CD268 (BAFF receptor). The therapy also incorporates a CD4+ helper peptide, universal cancer peptide 2 (UCP2), to enhance immune activation.
More news about: DelveInsight Business Research, LLP
Oct 16, 2025, 12:00 ET Keeper Security Recognized in the 2025 Gartner® Magic Quadrant™ for Privileged Access Management
vault with role-based access control, auditing and reporting. Secrets management: Integrate CI/CD pipelines, DevOps tools, custom software and multi-cloud environments into a fully-managed, zero-knowledge platform to secure infrastructure secrets
More news about: Keeper Security
Oct 16, 2025, 08:45 ET Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis
anti-BCMA CAR-T cell therapy which uses lentivirus vector to transfect autologous T cells. The CAR contains a fully human scFv, CD8a hinge and transmembrane, 4-1BB co-stimulatory and CD3ζactivation domains. Based on rigorous molecular structure screening and comprehensive in vitro and in vivo functional evaluations,
More news about: IASO Bio
Oct 16, 2025, 08:00 ET TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
More news about: Johnson & Johnson
Oct 15, 2025, 12:59 ET Folger Consort and the O.B. Hardison Poetry Series collaborate on "Virtuosos of Violin and Verse," an evening of Baroque music and poetry
works spanning three centuries, including one world premiere. A critically acclaimed international recording artist, Tatiana released her second solo CD album Meditations and Reflections (Steinway & Sons Label) in 2019. Paula Maust
More news about: Folger Shakespeare Library
Oct 15, 2025, 10:45 ET Boulder Sterilization Exec Speaks at Sterilization Summit 2025
services life sciences companies need to get their products to market. Boulder Sterilization provides quick-turn ethylene oxide (EO) and chlorine dioxide (CD) sterilization, final assembly and packaging services. Speaker topic: Alternative sterilization methods
More news about: Boulder Sterilization
Oct 15, 2025, 10:13 ET Hyperion Bank Launches Exclusive Money Market Offer Amidst Growth Recognition
a special 13-month Certificate of Deposit (CD) earning 4.25% APY (4.16% interest rate)†. This CD option gives customers seeking predictability an additional way to grow their savings with confidence. Both promotions require
More news about: Hyperion Bank
Oct 15, 2025, 09:11 ET Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
(GTB-5550) and autoimmune indications (GTB-7550)." The Phase 1 trial is testing GTB-3650 in patients with relapsed or refractory CD33-expressing blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These are patients whose cancers have
More news about: USA News Group
Oct 15, 2025, 08:45 ET Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
updates anticipated in the first quarter of 2026. The Phase 1 trial is evaluating GTB-3650 in patients with relapsed or refractory CD33-expressing blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These are particularly challenging patient
More news about: Equity Insider
Oct 15, 2025, 08:00 ET Ouro Medicines Announces Expansion of Clinical Development for OM336 in Sjögren's Disease and Idiopathic Inflammatory Myopathy
designed to induce T cell-dependent cellular cytotoxicity of target cells expressing BCMA. With a CD3-targeting arm engineered for the reduced induction of T cell cytokines, referred to as a 'detuned' CD3-targeting arm, OM336 is designed to avoid severe immune activation while retaining potency of target
More news about: Ouro Medicines
Oct 15, 2025, 07:00 ET Marengo Therapeutics to Present Key Pipeline Updates at 2025 SITC Annual Meeting and Reveal First Asset from TriSTAR™ Platform Targeting Nectin-4
Title: A novel TCRβ-directed IL-2 fusion molecule promotes memory CD8+ T cells with self-renewing properties in tumor ecosystems, further expanded by HDAC inhibition to elicit effective tumor suppression
More news about: Marengo Therapeutics
Oct 14, 2025, 12:00 ET Scaling Cloud and AI: MSI Highlights ORv3, DC-MHS, and MGX Solutions at 2025 OCP Global Summit
CD281-S4051-X2 2OU 2-node DC-MHS server supports a single AMD EPYC™ 9005 CPU up to 500W TDP per node, each node with 12 DDR5 DIMM slots, 12 front E3.S PCIe
More news about: MSI
Oct 14, 2025, 08:00 ET BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process
from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation
More news about: BioVaxys Technology Corp.
Oct 14, 2025, 06:15 ET Nandee Launches AI-Powered Mobile App Security Testing Platform
enterprise plans that support multiple mobile apps, advanced AI-driven vulnerability detection, and deeper integrations across multiple repositories and CI/CD environments. Today's launch of Nandee marks a significant step toward modernizing mobile application security. By delivering
More news about: Nandee